DOP2013000060A - Analogos de buprenorfina - Google Patents

Analogos de buprenorfina

Info

Publication number
DOP2013000060A
DOP2013000060A DO2013000060A DO2013000060A DOP2013000060A DO P2013000060 A DOP2013000060 A DO P2013000060A DO 2013000060 A DO2013000060 A DO 2013000060A DO 2013000060 A DO2013000060 A DO 2013000060A DO P2013000060 A DOP2013000060 A DO P2013000060A
Authority
DO
Dominican Republic
Prior art keywords
formula
buprenorfine
analogs
compounds
orl
Prior art date
Application number
DO2013000060A
Other languages
English (en)
Inventor
Donald J Kyle
Laykea Tafesse
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44903285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2013000060(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of DOP2013000060A publication Critical patent/DOP2013000060A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención está dirigida a los compuestos análogos de Buprenorfina de la Fórmula I, Fórmula IA o Fórmula IB que se enseñan a continuación, en los cuales R1, R2, R8, R3a, R3b, G, X, Z e Y son como se han definido en la descripción. Los compuestos de la invención son útiles para tratar el dolor, la constipación, y otras condiciones moduladas por la actividad de los receptores opioide y ORL-1.
DO2013000060A 2010-09-21 2013-03-20 Analogos de buprenorfina DOP2013000060A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38491210P 2010-09-21 2010-09-21
US201161503674P 2011-07-01 2011-07-01

Publications (1)

Publication Number Publication Date
DOP2013000060A true DOP2013000060A (es) 2013-04-30

Family

ID=44903285

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000060A DOP2013000060A (es) 2010-09-21 2013-03-20 Analogos de buprenorfina

Country Status (34)

Country Link
US (1) US9221831B2 (es)
EP (1) EP2619212B1 (es)
JP (2) JP5977240B2 (es)
KR (2) KR20150027315A (es)
CN (2) CN103154000A (es)
AR (1) AR083062A1 (es)
AU (1) AU2011306644B2 (es)
CA (1) CA2810356C (es)
CL (1) CL2013000732A1 (es)
CO (1) CO6690803A2 (es)
CR (1) CR20130129A (es)
CY (1) CY1117227T1 (es)
DK (1) DK2619212T3 (es)
DO (1) DOP2013000060A (es)
EA (1) EA201390422A1 (es)
EC (1) ECSP13012543A (es)
ES (1) ES2566828T3 (es)
HR (1) HRP20160281T1 (es)
HU (1) HUE027195T2 (es)
ME (1) ME02367B (es)
MX (1) MX2013003354A (es)
NI (1) NI201300032A (es)
NZ (1) NZ609200A (es)
PE (1) PE20140020A1 (es)
PH (1) PH12013500530A1 (es)
PL (1) PL2619212T3 (es)
RS (1) RS54579B1 (es)
SG (1) SG188300A1 (es)
SI (1) SI2619212T1 (es)
SM (1) SMT201600088B (es)
TW (2) TW201242968A (es)
UY (1) UY33618A (es)
WO (1) WO2012038813A1 (es)
ZA (1) ZA201301217B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
SI2582366T1 (sl) 2010-06-15 2016-02-29 Gruenenthal Gmbh Farmacevtska kombinacija za zdravljenje bolečine
CA2834164A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused benzoxazinones as ion channel modulators
NO3175985T3 (es) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
AU2012324012A1 (en) 2011-12-08 2013-06-27 Purdue Pharma L.P. Quaternized buprenorphine analogs
US9315514B2 (en) * 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
CA2890655A1 (en) 2012-11-09 2014-05-15 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US9175000B2 (en) 2012-12-07 2015-11-03 Purdue Pharma L.P. Buprenorphine analogs
WO2014118618A1 (en) 2013-01-31 2014-08-07 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
US9994571B2 (en) 2013-12-26 2018-06-12 Purdue Pharma L.P. 10-substituted morphinan hydantoins
WO2015097545A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
EP3087078B1 (en) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
EP3087057A4 (en) 2013-12-26 2017-06-28 Purdue Pharma LP Ring-contracted morphinans and the use thereof
EP3089982A4 (en) * 2013-12-26 2017-09-27 Purdue Pharma L.P. 7-beta analogs of orvinols
EP3086790A4 (en) 2013-12-27 2017-07-19 Purdue Pharma LP 6-substituted and 7-substituted morphinan analogs and the use thereof
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US10030021B2 (en) 2014-05-27 2018-07-24 Purdue Pharma L.P. Spirocyclic morphinans and use thereof
EP3154972A4 (en) 2014-06-13 2017-11-22 Purdue Pharma L.P. Azamophinan derivatives and use thereof
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
JP2018531955A (ja) * 2015-10-26 2018-11-01 オーフォームド,インコーポレイティド ブプレノルフィンのエチレングリコールエーテル
CN108884026B (zh) * 2016-03-22 2021-05-25 赫尔森保健股份公司 苯磺酰基不对称尿素及其医学用途
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
WO2018211331A1 (en) * 2017-05-19 2018-11-22 Evolva Sa Preparation of buprenorphine
JP2021104932A (ja) * 2018-03-30 2021-07-26 日本ケミファ株式会社 モルヒナン誘導体の製造方法
EP4577204A1 (en) * 2022-08-23 2025-07-02 Virginia Commonwealth University Multiple targeting opioid receptor ligands as novel analgesics with minimum abuse liability
EP4688749A2 (en) * 2023-04-04 2026-02-11 Board of Regents, The University of Texas System Methods of synthesizing 14-beta-aminomorphans and salts thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1136764A (en) * 1965-08-13 1968-12-18 Reckitt & Sons Ltd Derivatives of thebaine and oripavine
WO1998054168A1 (en) 1997-05-30 1998-12-03 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivatives
EP1072263A4 (en) 1998-03-26 2004-03-31 Japan Tobacco Inc AMID DERIVATIVES AND NOCICEPTINANT AGONISTS
BR0207978A (pt) 2001-03-02 2004-03-02 Euro Celtique Sa N-but-3enil norbuprenorfina e métodos de uso
US6740641B2 (en) 2001-07-27 2004-05-25 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
US6825205B2 (en) 2002-09-25 2004-11-30 Euro-Celtique S.A. N-substituted hydromorphones and the use thereof
DE60329515D1 (de) 2002-10-25 2009-11-12 Euro Celtique Sa Analoga und prodrugs von buprenorphin
US7202259B2 (en) 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US6958398B1 (en) 2002-12-30 2005-10-25 Euro-Celtique S.A. Methods for making thebaine or its acid salts
CN101553256B (zh) 2006-11-01 2013-01-30 普渡制药公司 苯基丙酰胺化合物及其用途
GB2447014A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
CA2707174C (en) 2007-11-30 2013-12-31 Purdue Pharma L.P. Benzomorphan compounds
AU2009277095B2 (en) 2008-07-30 2012-09-06 Purdue Pharma L.P. Buprenorphine analogs
US9133131B2 (en) 2011-11-15 2015-09-15 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
AU2012324012A1 (en) 2011-12-08 2013-06-27 Purdue Pharma L.P. Quaternized buprenorphine analogs
CA2870605A1 (en) 2012-05-11 2013-11-14 Purdue Pharma L.P. Benzomorphan compounds as opioid receptors modulators
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
CA2890655A1 (en) 2012-11-09 2014-05-15 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US9175000B2 (en) 2012-12-07 2015-11-03 Purdue Pharma L.P. Buprenorphine analogs
ES2631197T3 (es) 2012-12-14 2017-08-29 Purdue Pharma Lp Análogos de piridonamorfinano y actividad biológica sobre los receptores opiodes
EP2931726B1 (en) 2012-12-14 2017-01-25 Purdue Pharma LP Spirocyclic morphinans and their use
EP2931725B1 (en) 2012-12-14 2017-02-15 Purdue Pharma LP Nitrogen containing morphinan derivatives and the use thereof
TW201441198A (zh) 2012-12-28 2014-11-01 Purdue Pharma Lp 7,8-環嗎啡喃類似物
ES2653265T3 (es) 2012-12-28 2018-02-06 Purdue Pharma Lp Morfinanos sustituidos y el uso de éstos
WO2014118618A1 (en) 2013-01-31 2014-08-07 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
EP3089982A4 (en) 2013-12-26 2017-09-27 Purdue Pharma L.P. 7-beta analogs of orvinols
US9340542B2 (en) 2013-12-26 2016-05-17 Purdue Pharma L.P. Propellane-based compounds and the use thereof
EP3087078B1 (en) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
US9994571B2 (en) 2013-12-26 2018-06-12 Purdue Pharma L.P. 10-substituted morphinan hydantoins
EP3086790A4 (en) 2013-12-27 2017-07-19 Purdue Pharma LP 6-substituted and 7-substituted morphinan analogs and the use thereof
EP3089978B1 (en) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands

Also Published As

Publication number Publication date
HUE027195T2 (en) 2016-10-28
PH12013500530A1 (en) 2017-08-09
NI201300032A (es) 2014-01-13
SMT201600088B (it) 2016-04-29
JP5977240B2 (ja) 2016-08-24
CY1117227T1 (el) 2017-04-05
AU2011306644B2 (en) 2015-07-02
PL2619212T3 (pl) 2016-09-30
CN103154000A (zh) 2013-06-12
WO2012038813A1 (en) 2012-03-29
CL2013000732A1 (es) 2013-07-26
MX2013003354A (es) 2013-06-24
ME02367B (me) 2016-06-20
TW201242968A (en) 2012-11-01
EP2619212B1 (en) 2016-01-06
JP2016102115A (ja) 2016-06-02
CR20130129A (es) 2013-08-29
KR101630912B1 (ko) 2016-06-15
ZA201301217B (en) 2013-09-25
AU2011306644A1 (en) 2013-04-11
US9221831B2 (en) 2015-12-29
US20140057931A1 (en) 2014-02-27
NZ609200A (en) 2015-01-30
DK2619212T3 (en) 2016-03-21
RS54579B1 (sr) 2016-06-30
SG188300A1 (en) 2013-04-30
SI2619212T1 (sl) 2016-04-29
JP2013543488A (ja) 2013-12-05
HK1187045A1 (en) 2014-03-28
KR20130097210A (ko) 2013-09-02
AR083062A1 (es) 2013-01-30
EP2619212A1 (en) 2013-07-31
TW201422621A (zh) 2014-06-16
ECSP13012543A (es) 2013-06-28
CA2810356C (en) 2016-06-14
EA201390422A1 (ru) 2014-01-30
CO6690803A2 (es) 2013-06-17
CA2810356A1 (en) 2012-03-29
UY33618A (es) 2012-03-30
CN105399751A (zh) 2016-03-16
KR20150027315A (ko) 2015-03-11
PE20140020A1 (es) 2014-01-31
ES2566828T3 (es) 2016-04-15
HRP20160281T1 (hr) 2016-04-08

Similar Documents

Publication Publication Date Title
ECSP13012543A (es) Análogos de buprenorfina
UA104004C2 (uk) Аналоги бупренорфіну
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
CR20130295A (es) Análogos de glucagón que presentan actividad de receptor de gip
CR20130671A (es) Antagonistas de trpv4
ZA201301902B (en) Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CR20150359A (es) Nuevos compuestos bicíclicos y su uso como agentes antibacterianos e inhibidores de b-lactamasa
UY33815A (es) Composiciones y métodos para modular el fxr
ECSP12011902A (es) Compuestos de espiropiperidina como antagonistas
PE20151065A1 (es) Novedosos derivados de bencimidazol como antagonistas de ep4
SV2016005192A (es) Composiciones y métodos para modular los receptores x farnesoides
CR20150370A (es) Compuestos antivirales
PE20171444A1 (es) Compuestos antivirales
MX2019003738A (es) Compuestos antivirales.
DOP2015000076A (es) Benzamidas
WO2014140784A3 (en) Buprenorphine analogs
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
BR112014000306A2 (pt) uma nova composição terapêutica contendo apomorfina como ingrediente ativo
CR20130597A (es) Isoxazolinas como agentes terapèuticos
CO6761304A2 (es) Nuevos compuestos de bezodioxol-piperazina
PE20150928A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
CR20120592A (es) Intermedios de agomelatina y métodos de preparación de estos
EP2830614A4 (en) CYCLIC PRODRUGS FROM DUOCARMYCIN ANALOGUE
TN2013000066A1 (en) Buprenorphine analogs
CR20130105A (es) Derivados dihidrobenzoxatiazepinas, su preparación, composiciones farmacéuticas y utilización como moduladores de los receptores ampa